{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:12:50Z","timestamp":1792800770794,"version":"4.5.0"},"reference-count":127,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82472831"],"award-info":[{"award-number":["82472831"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shenzhen Medical Research Fund","award":["A2503095"],"award-info":[{"award-number":["A2503095"]}]},{"name":"Natural Science Foundation of Shenzhen Science and Technology Innovation Committee","award":["JCYJ20220531093800001"],"award-info":[{"award-number":["JCYJ20220531093800001"]}],"id":[{"id":"https:\/\/ror.org\/017n8df75","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Basic and Applied Basic Research Funding of Guangdong Province","award":["2023A1515220164"],"award-info":[{"award-number":["2023A1515220164"]}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2024A1515010330"],"award-info":[{"award-number":["2024A1515010330"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Health Commission of the People's Republic of China - Zhejiang Province Jointly Constructed Project, Zhejiang Province Medical and Health Science and Technology Plan","award":["WKJ-ZJ-2517"],"award-info":[{"award-number":["WKJ-ZJ-2517"]}],"id":[{"id":"https:\/\/ror.org\/04bdenw41","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Clinical-Basic Joint Research Project of Zhejiang Provincial People's Hospital Affiliated with Hangzhou Medical College","award":["C-2025-YXLH09"],"award-info":[{"award-number":["C-2025-YXLH09"]}],"id":[{"id":"https:\/\/ror.org\/05gpas306","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Commun Signal"],"DOI":"10.1186\/s12964-026-02795-2","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:54:33Z","timestamp":1774400073000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Deciphering double-negative prostate cancer: from aggressive subtype to novel therapeutic paradigms"],"prefix":"10.1186","volume":"24","author":[{"given":"Jie","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruicheng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhouting","family":"Tuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uzoamaka Adaobi","family":"Okoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhipeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Premkamon","family":"Chaipanichkul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siang Boon","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dengxiong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaojie","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheema","family":"Umber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dechao","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"issue":"10","key":"2795_CR1","doi-asserted-by":"publisher","first-page":"4492","DOI":"10.1172\/JCI128212","volume":"129","author":"MP Labrecque","year":"2019","unstructured":"Labrecque MP, Coleman IM, Brown LG, True LD, Kollath L, Lakely B, et al. Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer. J Clin Invest. 2019;129(10):4492\u2013505. Epub 20190730. PubMed PMID: 31361600; PubMed Central PMCID: PMC6763249. https:\/\/doi.org\/10.1172\/JCI128212.","journal-title":"J Clin Invest"},{"issue":"11","key":"2795_CR2","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.neo.2020.09.002","volume":"22","author":"JE Vellky","year":"2020","unstructured":"Vellky JE, Ricke WA. Development and prevalence of castration-resistant prostate cancer subtypes. Neoplasia. 2020;22(11):566\u201375. Epub 20200925. PubMed PMID: 32980775; PubMed Central PMCID: PMC7522286. https:\/\/doi.org\/10.1016\/j.neo.2020.09.002.","journal-title":"Neoplasia"},{"issue":"16","key":"2795_CR3","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.1158\/0008-5472.CAN-23-0593","volume":"83","author":"A Lundberg","year":"2023","unstructured":"Lundberg A, Zhang M, Aggarwal R, Li H, Zhang L, Foye A, et al. The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer. Cancer Res. 2023;83(16):2763\u201374. https:\/\/doi.org\/10.1158\/0008-5472.CAN-23-0593. PubMed PMID: 37289025; PubMed Central PMCID: PMC10425725.","journal-title":"Cancer Res"},{"key":"2795_CR4","doi-asserted-by":"publisher","unstructured":"Bluemn EG, Coleman IM, Lucas JM, Coleman RT, Hernandez-Lopez S, Tharakan R et al. Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling. Cancer Cell. 2017;32(4):474\u2009\u2013\u200989 e6. PubMed PMID: 29017058; PubMed Central PMCID: PMC5750052. https:\/\/doi.org\/10.1016\/j.ccell.2017.09.003.","DOI":"10.1016\/j.ccell.2017.09.003"},{"issue":"7","key":"2795_CR5","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/s0046-8177(03)00190-4","volume":"34","author":"MP Roudier","year":"2003","unstructured":"Roudier MP, True LD, Higano CS, Vesselle H, Ellis W, Lange P, et al. Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. Hum Pathol. 2003;34(7):646\u201353. https:\/\/doi.org\/10.1016\/s0046-8177(03)00190-4. PubMed PMID: 12874759.","journal-title":"Hum Pathol"},{"key":"2795_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2019.06.009","author":"W Su","year":"2019","unstructured":"Su W, Han HH, Wang Y, Zhang B, Zhou B, Cheng Y, et al. Cancer Cell. The Polycomb Repressor Complex 1 Drives Double-Negative Prostate Cancer Metastasis by Coordinating Stemness and Immune Suppression. 2019;36(2):139\u201355. https:\/\/doi.org\/10.1016\/j.ccell.2019.06.009. e10. Epub 20190718."},{"issue":"4","key":"2795_CR7","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1097\/JU.0000000000000732.01","volume":"203","author":"A Atala","year":"2020","unstructured":"Atala A, Re. The Polycomb Repressor Complex 1 Drives Double-Negative Prostate Cancer Metastasis by Coordinating Stemness and Immune Suppression. J Urol. 2020;203(4):665\u20136. Epub 20200113. PubMed PMID: 31928476. https:\/\/doi.org\/10.1097\/JU.0000000000000732.01.","journal-title":"J Urol"},{"issue":"6596","key":"2795_CR8","doi-asserted-by":"publisher","first-page":"eabe1505","DOI":"10.1126\/science.abe1505","volume":"376","author":"F Tang","year":"2022","unstructured":"Tang F, Xu D, Wang S, Wong CK, Martinez-Fundichely A, Lee CJ, et al. Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets. Science. 2022;376(6596):eabe1505. https:\/\/doi.org\/10.1126\/science.abe1505. Epub 20220527.","journal-title":"Science"},{"issue":"6","key":"2795_CR9","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1002\/iju5.12363","volume":"4","author":"H Sawazaki","year":"2021","unstructured":"Sawazaki H, Asano A, Kitamura Y, Katsuta J, Ito Y. Androgen receptor-neuroendocrine double-negative tumor with squamous differentiation arising from treatment-refractory metastatic castration-resistant prostate cancer. IJU Case Rep. 2021;4(6):417\u201320. https:\/\/doi.org\/10.1002\/iju5.12363. Epub 20210822.","journal-title":"IJU Case Rep"},{"key":"2795_CR10","doi-asserted-by":"publisher","unstructured":"Wang Z, Wang J, Li D, Wu R, Huang J, Ye L, et al. Novel hormone therapies for advanced prostate cancer: understanding and countering drug resistance. J Pharm Anal. 2025;101232. https:\/\/doi.org\/10.1016\/j.jpha.2025.101232.","DOI":"10.1016\/j.jpha.2025.101232"},{"key":"2795_CR11","doi-asserted-by":"publisher","first-page":"e18761429350210","DOI":"10.2174\/0118761429350210250102131611","volume":"17","author":"AS Carranza-Aranda","year":"2024","unstructured":"Carranza-Aranda AS, Santerre A, Segura-Cabrera A, Cardenas-Vargas A, Martinez-Velazquez M, Hernandez-Gutierrez R, et al. Chrysin: A Potential Antiandrogen Ligand to Mutated Androgen Receptors in Prostate Cancer. Curr Mol Pharmacol. 2024;17:e18761429350210. PubMed PMID: 39806979. https:\/\/doi.org\/10.2174\/0118761429350210250102131611.","journal-title":"Curr Mol Pharmacol"},{"issue":"5","key":"2795_CR12","doi-asserted-by":"publisher","first-page":"719","DOI":"10.6004\/jnccn.2014.0073","volume":"12","author":"R Aggarwal","year":"2014","unstructured":"Aggarwal R, Zhang T, Small EJ, Armstrong AJ. Neuroendocrine prostate cancer: subtypes, biology, and clinical outcomes. J Natl Compr Canc Netw. 2014;12(5):719\u201326. 0073. PubMed PMID: 24812138.","journal-title":"J Natl Compr Canc Netw"},{"issue":"Pt 3","key":"2795_CR13","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.semcancer.2022.05.007","volume":"86","author":"S Liu","year":"2022","unstructured":"Liu S, Alabi BR, Yin Q, Stoyanova T. Molecular mechanisms underlying the development of neuroendocrine prostate cancer. Semin Cancer Biol. 2022;86(Pt 3):57\u201368. https:\/\/doi.org\/10.1016\/j.semcancer.2022.05.007. Epub 20220518.","journal-title":"Semin Cancer Biol"},{"issue":"7","key":"2795_CR14","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.trecan.2019.05.008","volume":"5","author":"S Laudato","year":"2019","unstructured":"Laudato S, Aparicio A, Giancotti FG. Clonal Evolution and Epithelial Plasticity in the Emergence of AR-Independent Prostate Carcinoma. Trends Cancer. 2019;5(7):440\u201355. https:\/\/doi.org\/10.1016\/j.trecan.2019.05.008. Epub 20190629.","journal-title":"Trends Cancer"},{"key":"2795_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2025.04.002","author":"J Guo","year":"2025","unstructured":"Guo J, Li N, Liu Q, Hao Z, Zhu G, Wang X, et al. KMT2C deficiency drives transdifferentiation of double-negative prostate cancer and confer resistance to AR-targeted therapy. Cancer Cell. 2025. https:\/\/doi.org\/10.1016\/j.ccell.2025.04.002. Epub 20250422.","journal-title":"Cancer Cell"},{"issue":"6611","key":"2795_CR16","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1126\/science.abn0478","volume":"377","author":"JM Chan","year":"2022","unstructured":"Chan JM, Zaidi S, Love JR, Zhao JL, Setty M, Wadosky KM, et al. Lineage plasticity in prostate cancer depends on JAK\/STAT inflammatory signaling. Science. 2022;377(6611):1180\u201391. https:\/\/doi.org\/10.1126\/science.abn0478. Epub 20220818.","journal-title":"Science"},{"issue":"6","key":"2795_CR17","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41571-020-0340-z","volume":"17","author":"A Quintanal-Villalonga","year":"2020","unstructured":"Quintanal-Villalonga A, Chan JM, Yu HA, Pe\u2019er D, Sawyers CL, Sen T, et al. Lineage plasticity in cancer: a shared pathway of therapeutic resistance. Nat Rev Clin Oncol. 2020;17(6):360\u201371. https:\/\/doi.org\/10.1038\/s41571-020-0340-z. Epub 20200309.","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"2795_CR18","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/nrurol.2018.22","volume":"15","author":"AH Davies","year":"2018","unstructured":"Davies AH, Beltran H, Zoubeidi A. Cellular plasticity and the neuroendocrine phenotype in prostate cancer. Nat Rev Urol. 2018;15(5):271\u201386. https:\/\/doi.org\/10.1038\/nrurol.2018.22. Epub 20180220.","journal-title":"Nat Rev Urol"},{"issue":"18","key":"2795_CR19","doi-asserted-by":"publisher","first-page":"3086","DOI":"10.1158\/0008-5472.CAN-24-0890","volume":"84","author":"R Shrestha","year":"2024","unstructured":"Shrestha R, Chesner LN, Zhang M, Zhou S, Foye A, Lundberg A, et al. An Atlas of Accessible Chromatin in Advanced Prostate Cancer Reveals the Epigenetic Evolution during Tumor Progression. Cancer Res. 2024;84(18):3086\u2013100. https:\/\/doi.org\/10.1158\/0008-5472.CAN-24-0890. PubMed PMID: 38990734.","journal-title":"Cancer Res"},{"issue":"1","key":"2795_CR20","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/s41698-024-00667-x","volume":"8","author":"S Cheng","year":"2024","unstructured":"Cheng S, Li L, Yeh Y, Shi Y, Franco O, Corey E, et al. Unveiling novel double-negative prostate cancer subtypes through single-cell RNA sequencing analysis. NPJ Precis Oncol. 2024;8(1):171. https:\/\/doi.org\/10.1038\/s41698-024-00667-x. Epub 20240802.","journal-title":"NPJ Precis Oncol"},{"issue":"1","key":"2795_CR21","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1097\/PAS.0b013e318058a96b","volume":"32","author":"W Wang","year":"2008","unstructured":"Wang W, Epstein JI. Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases. Am J Surg Pathol. 2008;32(1):65\u201371. https:\/\/doi.org\/10.1097\/PAS.0b013e318058a96b. PubMed PMID: 18162772.","journal-title":"Am J Surg Pathol"},{"key":"2795_CR22","doi-asserted-by":"publisher","unstructured":"Masur J, Ratan A, Wierbilowicz K, Ayanambakkam A, Churchman ML, Graham LS et al. Clinical and Genomic Features of Androgen Indifferent Prostate Cancer. Int J Mol Sci. 2025;26(2). Epub 20250115. https:\/\/doi.org\/10.3390\/ijms26020679. PubMed PMID: 39859392; PubMed Central PMCID: PMC11765751.","DOI":"10.3390\/ijms26020679"},{"key":"2795_CR23","doi-asserted-by":"publisher","unstructured":"Frank S, Nelson P, Vasioukhin V. Recent advances in prostate cancer research: large-scale genomic analyses reveal novel driver mutations and DNA repair defects. F1000Res. 2018;7. https:\/\/doi.org\/10.12688\/f1000research.14499.1. Epub 20180802.","DOI":"10.12688\/f1000research.14499.1"},{"issue":"3","key":"2795_CR24","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1007\/s00120-024-02511-3","volume":"64","author":"G von Amsberg","year":"2025","unstructured":"von Amsberg G, Dyshlovoy S, Kaune M. [Aggressive variant prostate cancer and transdifferentiated neuroendocrine prostate cancer: from diagnosis to therapy]. Urologie. 2025;64(3):246\u201355. https:\/\/doi.org\/10.1007\/s00120-024-02511-3. Epub 20250210.","journal-title":"Urologie"},{"issue":"1","key":"2795_CR25","doi-asserted-by":"publisher","first-page":"90","DOI":"10.21147\/j.issn.1000-9604.2025.01.07","volume":"37","author":"T Ding","year":"2025","unstructured":"Ding T, He L, Lin G, Xu L, Zhu Y, Wang X, et al. Integrated analysis of single-cell and bulk transcriptomes uncovers clinically relevant molecular subtypes in human prostate cancer. Chin J Cancer Res. 2025;37(1):90\u2013114. https:\/\/doi.org\/10.21147\/j.issn.1000-9604.2025.01.07. PubMed PMID: 40078560; PubMed Central PMCID: PMC11893346.","journal-title":"Chin J Cancer Res"},{"issue":"5","key":"2795_CR26","doi-asserted-by":"publisher","first-page":"796","DOI":"10.21147\/j.issn.1000","volume":"37","author":"W Xia","year":"2025","unstructured":"Xia W, Liu J, Chen R, Feng J, Wu L, Wang Y, et al. Molecular subtypes and prognostic signature rooted in disulfidptosis highlight tumor microenvironment in lung adenocarcinoma. Chin J Cancer Res. 2025;37(5):796\u2013820. https:\/\/doi.org\/10.21147\/j.issn.1000. PubMed PMID: 41246257; PubMed Central PMCID: PMC12614471.","journal-title":"Chin J Cancer Res"},{"issue":"6","key":"2795_CR27","doi-asserted-by":"publisher","first-page":"e2415308122","DOI":"10.1073\/pnas.2415308122","volume":"122","author":"SP Pitzen","year":"2025","unstructured":"Pitzen SP, Rudenick AN, Qiu Y, Zhang W, Munro SA, McCluskey BM, et al. Comparative transcriptomics reveals a mixed basal, club, and hillock epithelial cell identity in castration-resistant prostate cancer. Proc Natl Acad Sci U S A. 2025;122(6):e2415308122. https:\/\/doi.org\/10.1073\/pnas.2415308122. Epub 20250206.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2795_CR28","doi-asserted-by":"publisher","unstructured":"Brennen WN, Zhu Y, Coleman IM, Dalrymple SL, Antony L, Patel RA et al. Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancer. JCI Insight. 2021;6(8). Epub 20210422. https:\/\/doi.org\/10.1172\/jci.insight.146827. PubMed PMID: 33724955; PubMed Central PMCID: PMC8119192.","DOI":"10.1172\/jci.insight.146827"},{"issue":"1","key":"2795_CR29","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s40779-024-00526-7","volume":"11","author":"DC Feng","year":"2024","unstructured":"Feng DC, Zhu WZ, Wang J, Li DX, Shi X, Xiong Q, et al. The implications of single-cell RNA-seq analysis in prostate cancer: unraveling tumor heterogeneity, therapeutic implications and pathways towards personalized therapy. Mil Med Res. 2024;11(1):21. https:\/\/doi.org\/10.1186\/s40779-024-00526-7. Epub 20240411.","journal-title":"Mil Med Res"},{"key":"2795_CR30","doi-asserted-by":"publisher","unstructured":"Li D, Yu Q, Shao F, Wang J, Wu R, Guo Y et al. Decoding the crossroads of aging and cancer through single-cell analysis: Implications for precision oncology. Int J Cancer. 2025. Epub 20250423. https:\/\/doi.org\/10.1002\/ijc.35456. PubMed PMID: 40268523.","DOI":"10.1002\/ijc.35456"},{"key":"2795_CR31","doi-asserted-by":"publisher","unstructured":"Zhang W, Liu T, Liu T, Zhang Y, Zhao Z, Zhang X et al. Exploration and Application of Malignant Cell Heterogeneity Analysis with Single-Cell Transcriptome Sequencing Technology. Aging Dis. 2025. Epub 20250725. PubMed PMID: 40768639. https:\/\/doi.org\/10.14336\/AD.2025.0836.","DOI":"10.14336\/AD.2025.0836"},{"issue":"6","key":"2795_CR32","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1038\/s41573-023-00688-4","volume":"22","author":"B Van de Sande","year":"2023","unstructured":"Van de Sande B, Lee JS, Mutasa-Gottgens E, Naughton B, Bacon W, Manning J, et al. Applications of single-cell RNA sequencing in drug discovery and development. Nat Rev Drug Discov. 2023;22(6):496\u2013520. https:\/\/doi.org\/10.1038\/s41573-023-00688-4. Epub 20230428.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"2795_CR33","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1002\/pros.24082","volume":"81","author":"H Iwamoto","year":"2021","unstructured":"Iwamoto H, Izumi K, Shimada T, Kano H, Kadomoto S, Makino T, et al. Androgen receptor signaling-targeted therapy and taxane chemotherapy induce visceral metastasis in castration-resistant prostate cancer. Prostate. 2021;81(1):72\u201380. Epub 20201013. PubMed PMID: 33047850. https:\/\/doi.org\/10.1002\/pros.24082.","journal-title":"Prostate"},{"issue":"5","key":"2795_CR34","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1056\/NEJMoa1405095","volume":"371","author":"TM Beer","year":"2014","unstructured":"Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371(5):424\u201333. Epub 20140601. PubMed PMID: 24881730; PubMed Central PMCID: PMC4418931. https:\/\/doi.org\/10.1056\/NEJMoa1405095.","journal-title":"N Engl J Med"},{"issue":"2","key":"2795_CR35","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa1209096","volume":"368","author":"CJ Ryan","year":"2013","unstructured":"Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368(2):138\u201348. Epub 20121210. PubMed PMID: 23228172; PubMed Central PMCID: PMC3683570. https:\/\/doi.org\/10.1056\/NEJMoa1209096.","journal-title":"N Engl J Med"},{"issue":"13","key":"2795_CR36","doi-asserted-by":"publisher","first-page":"3621","DOI":"10.1158\/1078-0432.CCR-12-3791","volume":"19","author":"AM Aparicio","year":"2013","unstructured":"Aparicio AM, Harzstark AL, Corn PG, Wen S, Araujo JC, Tu SM, et al. Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res. 2013;19(13):3621\u201330. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-3791. Epub 20130506.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2795_CR37","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ctrv.2013.07.008","volume":"40","author":"S Wen","year":"2014","unstructured":"Wen S, Niu Y, Lee SO, Chang C. Androgen receptor (AR) positive vs negative roles in prostate cancer cell deaths including apoptosis, anoikis, entosis, necrosis and autophagic cell death. Cancer Treat Rev. 2014;40(1):31\u201340. PubMed PMID: 23993415; PubMed Central PMCID: PMC3833078.","journal-title":"Cancer Treat Rev"},{"issue":"11","key":"2795_CR38","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1038\/ng.3419","volume":"47","author":"MM Pomerantz","year":"2015","unstructured":"Pomerantz MM, Li F, Takeda DY, Lenci R, Chonkar A, Chabot M, et al. The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis. Nat Genet. 2015;47(11):1346\u201351. https:\/\/doi.org\/10.1038\/ng.3419. Epub 20151012.","journal-title":"Nat Genet"},{"issue":"3","key":"2795_CR39","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nm.4045","volume":"22","author":"H Beltran","year":"2016","unstructured":"Beltran H, Prandi D, Mosquera JM, Benelli M, Puca L, Cyrta J, et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med. 2016;22(3):298\u2013305. Epub 20160208. PubMed PMID: 26855148; PubMed Central PMCID: PMC4777652. https:\/\/doi.org\/10.1038\/nm.4045.","journal-title":"Nat Med"},{"issue":"10","key":"2795_CR40","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1016\/j.ctrv.2015.08.002","volume":"41","author":"C Buttigliero","year":"2015","unstructured":"Buttigliero C, Tucci M, Bertaglia V, Vignani F, Bironzo P, Di Maio M, et al. Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer. Cancer Treat Rev. 2015;41(10):884\u201392. 002. PubMed PMID: 26342718.","journal-title":"Cancer Treat Rev"},{"issue":"7406","key":"2795_CR41","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/nature11125","volume":"487","author":"CS Grasso","year":"2012","unstructured":"Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature. 2012;487(7406):239\u201343. https:\/\/doi.org\/10.1038\/nature11125. PubMed PMID: 22722839; PubMed Central PMCID: PMC3396711.","journal-title":"Nature"},{"issue":"1","key":"2795_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1593\/neo.121550","volume":"15","author":"JM Mosquera","year":"2013","unstructured":"Mosquera JM, Beltran H, Park K, MacDonald TY, Robinson BD, Tagawa ST, et al. Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer. Neoplasia. 2013;15(1):1\u201310. https:\/\/doi.org\/10.1593\/neo.121550. PubMed PMID: 23358695; PubMed Central PMCID: PMC3556934.","journal-title":"Neoplasia"},{"issue":"4","key":"2795_CR43","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.ccell.2016.09.005","volume":"30","author":"E Dardenne","year":"2016","unstructured":"Dardenne E, Beltran H, Benelli M, Gayvert K, Berger A, Puca L, et al. N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer. Cancer Cell. 2016;30(4):563\u201377. https:\/\/doi.org\/10.1016\/j.ccell.2016.09.005. PubMed PMID: 27728805; PubMed Central PMCID: PMC5540451.","journal-title":"Cancer Cell"},{"issue":"5","key":"2795_CR44","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","volume":"161","author":"D Robinson","year":"2015","unstructured":"Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;161(5):1215\u201328. https:\/\/doi.org\/10.1016\/j.cell.2015.05.001. PubMed PMID: 26000489; PubMed Central PMCID: PMC4484602.","journal-title":"Cell"},{"issue":"1","key":"2795_CR45","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.eururo.2016.04.028","volume":"71","author":"Y Li","year":"2017","unstructured":"Li Y, Donmez N, Sahinalp C, Xie N, Wang Y, Xue H, et al. SRRM4 Drives Neuroendocrine Transdifferentiation of Prostate Adenocarcinoma Under Androgen Receptor Pathway Inhibition. Eur Urol. 2017;71(1):68\u201378. https:\/\/doi.org\/10.1016\/j.eururo.2016.04.028. Epub 20160511.","journal-title":"Eur Urol"},{"key":"2795_CR46","doi-asserted-by":"publisher","unstructured":"Zhang J, Chen Z, Mao Y, He Y, Wu X, Wu J et al. ID2 Promotes Lineage Transition of Prostate Cancer through FGFR and JAK-STAT Signaling. Cancers (Basel). 2024;16(2). Epub 20240117. https:\/\/doi.org\/10.3390\/cancers16020392. PubMed PMID: 38254880; PubMed Central PMCID: PMC10814654.","DOI":"10.3390\/cancers16020392"},{"key":"2795_CR47","doi-asserted-by":"publisher","unstructured":"Puca L, Gavyert K, Sailer V, Conteduca V, Dardenne E, Sigouros M, et al. Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer. Sci Transl Med. 2019;11(484). https:\/\/doi.org\/10.1126\/scitranslmed.aav0891. PubMed PMID: 30894499; PubMed Central PMCID: PMC6525633.","DOI":"10.1126\/scitranslmed.aav0891"},{"key":"2795_CR48","doi-asserted-by":"publisher","unstructured":"Cai M, Zheng F, Ren YZ, Zhen C, Fu D, Song XL et al. New Insights into Potential Therapeutic Targets for Neuroendocrine Prostate Cancer: From Bench to Clinic. Research (Wash D C). 2025;8:0791. Epub 20250731. https:\/\/doi.org\/10.34133\/research.0791. PubMed PMID: 40746825; PubMed Central PMCID: PMC12311307.","DOI":"10.34133\/research.0791"},{"issue":"8","key":"2795_CR49","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1158\/2159-8290.CD-23-0225","volume":"13","author":"A Davies","year":"2023","unstructured":"Davies A, Zoubeidi A, Beltran H, Selth LA. The Transcriptional and Epigenetic Landscape of Cancer Cell Lineage Plasticity. Cancer Discov. 2023;13(8):1771\u201388. https:\/\/doi.org\/10.1158\/2159-8290.CD-23-0225. PubMed PMID: 37470668; PubMed Central PMCID: PMC10527883.","journal-title":"Cancer Discov"},{"issue":"11","key":"2795_CR50","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/s41568-022-00524-8","volume":"22","author":"D Senft","year":"2022","unstructured":"Senft D. Drivers of lineage plasticity. Nat Rev Cancer. 2022;22(11):605. https:\/\/doi.org\/10.1038\/s41568-022-00524-8. PubMed PMID: 36207488.","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"2795_CR51","doi-asserted-by":"publisher","first-page":"3924","DOI":"10.1172\/JCI127961","volume":"129","author":"A Berger","year":"2019","unstructured":"Berger A, Brady NJ, Bareja R, Robinson B, Conteduca V, Augello MA, et al. N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer. J Clin Invest. 2019;129(9):3924\u201340. Epub 20190701. PubMed PMID: 31260412; PubMed Central PMCID: PMC6715370. https:\/\/doi.org\/10.1172\/JCI127961.","journal-title":"J Clin Invest"},{"key":"2795_CR52","doi-asserted-by":"publisher","unstructured":"Wang J, Shao F, Yu QX, Ye L, Wusiman D, Wu R et al. The Common Hallmarks and Interconnected Pathways of Aging, Circadian Rhythms, and Cancer: Implications for Therapeutic Strategies. Research (Wash D C). 2025;8:0612. Epub 20250305. https:\/\/doi.org\/10.34133\/research.0612. PubMed PMID: 40046513; PubMed Central PMCID: PMC11880593.","DOI":"10.34133\/research.0612"},{"issue":"3","key":"2795_CR53","doi-asserted-by":"publisher","first-page":"322","DOI":"10.21147\/j.issn.1000-9604.2024.03.08","volume":"36","author":"Z Fan","year":"2024","unstructured":"Fan Z, Dong S, Wang N, Khawar MB, Wang J, Sun H. Unlocking epigenetics for precision treatment of Ewing\u2019s sarcoma. Chin J Cancer Res. 2024;36(3):322\u201340. https:\/\/doi.org\/10.21147\/j.issn.1000-9604.2024.03.08. PubMed PMID: 38988487; PubMed Central PMCID: PMC11230886.","journal-title":"Chin J Cancer Res"},{"issue":"12","key":"2795_CR54","doi-asserted-by":"publisher","first-page":"3028","DOI":"10.1158\/2159-8290.CD-20-1863","volume":"11","author":"A Quintanal-Villalonga","year":"2021","unstructured":"Quintanal-Villalonga A, Taniguchi H, Zhan YA, Hasan MM, Chavan SS, Meng F, et al. Multiomic Analysis of Lung Tumors Defines Pathways Activated in Neuroendocrine Transformation. Cancer Discov. 2021;11(12):3028\u201347. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-1863. PubMed PMID: 34155000; PubMed Central PMCID: PMC9437746.","journal-title":"Cancer Discov"},{"issue":"11","key":"2795_CR55","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.ccell.2022.10.011","volume":"40","author":"M Han","year":"2022","unstructured":"Han M, Li F, Zhang Y, Dai P, He J, Li Y, et al. FOXA2 drives lineage plasticity and KIT pathway activation in neuroendocrine prostate cancer. Cancer Cell. 2022;40(11):1306\u201323. https:\/\/doi.org\/10.1016\/j.ccell.2022.10.011. e8. Epub 20221103.","journal-title":"Cancer Cell"},{"issue":"1","key":"2795_CR56","doi-asserted-by":"publisher","first-page":"4914","DOI":"10.1038\/s41467-024-49234-9","volume":"15","author":"Z Wang","year":"2024","unstructured":"Wang Z, Townley SL, Zhang S, Liu M, Li M, Labaf M, et al. FOXA2 rewires AP-1 for transcriptional reprogramming and lineage plasticity in prostate cancer. Nat Commun. 2024;15(1):4914. https:\/\/doi.org\/10.1038\/s41467-024-49234-9. Epub 20240608.","journal-title":"Nat Commun"},{"key":"2795_CR57","doi-asserted-by":"publisher","first-page":"1611693","DOI":"10.3389\/pore.2024.1611693","volume":"30","author":"Z Han","year":"2024","unstructured":"Han Z, Yang F, Wang F, Zheng H, Chen X, Meng H, et al. Advances in combined neuroendocrine carcinoma of lung cancer. Pathol Oncol Res. 2024;30:1611693. Epub 20240514. PubMed PMID: 38807858; PubMed Central PMCID: PMC11130380. https:\/\/doi.org\/10.3389\/pore.2024.1611693.","journal-title":"Pathol Oncol Res"},{"key":"2795_CR58","doi-asserted-by":"publisher","first-page":"1611743","DOI":"10.3389\/pore.2024.1611743","volume":"30","author":"GM Fur","year":"2024","unstructured":"Fur GM, Nemes K, Mago E, Beno AA, Topolcsanyi P, Moldvay J, et al. Applied models and molecular characteristics of small cell lung cancer. Pathol Oncol Res. 2024;30:1611743. Epub 20240422. PubMed PMID: 38711976; PubMed Central PMCID: PMC11070512. https:\/\/doi.org\/10.3389\/pore.2024.1611743.","journal-title":"Pathol Oncol Res"},{"issue":"2","key":"2795_CR59","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/pin.13507","volume":"75","author":"T Yamakado","year":"2025","unstructured":"Yamakado T, Sato-Yazawa H, Ishii J, Kashiwagi K, Kimura T, Tanei ZI, et al. Spontaneous Transformation from Lung Adenocarcinoma to MYC-amplified Large Cell Neuroendocrine Carcinoma. Pathol Int. 2025;75(2):105\u201313. Epub 20250127. PubMed PMID: 39868963. https:\/\/doi.org\/10.1111\/pin.13507.","journal-title":"Pathol Int"},{"issue":"8","key":"2795_CR60","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1038\/s43018-023-00595-y","volume":"4","author":"A Perez-Gonzalez","year":"2023","unstructured":"Perez-Gonzalez A, Bevant K, Blanpain C. Cancer cell plasticity during tumor progression, metastasis and response to therapy. Nat Cancer. 2023;4(8):1063\u201382. https:\/\/doi.org\/10.1038\/s43018-023-00595-y. Epub 20230803.","journal-title":"Nat Cancer"},{"issue":"1","key":"2795_CR61","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41422-024-01025-z","volume":"35","author":"F Li","year":"2025","unstructured":"Li F, Dai P, Shi H, Zhang Y, He J, Gopalan A, et al. LKB1 inactivation promotes epigenetic remodeling-induced lineage plasticity and antiandrogen resistance in prostate cancer. Cell Res. 2025;35(1):59\u201371. https:\/\/doi.org\/10.1038\/s41422-024-01025-z. Epub 20250102.","journal-title":"Cell Res"},{"issue":"12","key":"2795_CR62","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.tibs.2013.09","volume":"38","author":"HM Herz","year":"2013","unstructured":"Herz HM, Garruss A, Shilatifard A. SET for life: biochemical activities and biological functions of SET domain-containing proteins. Trends Biochem Sci. 2013;38(12):621\u201339. https:\/\/doi.org\/10.1016\/j.tibs.2013.09. Epub 20131020.","journal-title":"Trends Biochem Sci"},{"issue":"1","key":"2795_CR63","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jid.2022.06.025","volume":"143","author":"S Huang","year":"2023","unstructured":"Huang S, Zhen Y, Yin X, Yang Z, Li X, Wang R, et al. KMT2C Induced by FABP5P3 Aggravates Keratinocyte Hyperproliferation and Psoriasiform Skin Inflammation by Upregulating the Transcription of PIK3R3. J Invest Dermatol. 2023;143(1):37\u201347. https:\/\/doi.org\/10.1016\/j.jid.2022.06.025. e8. Epub 20220721.","journal-title":"J Invest Dermatol"},{"issue":"10","key":"2795_CR64","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1101\/gad.374006","volume":"20","author":"V Vives","year":"2006","unstructured":"Vives V, Su J, Zhong S, Ratnayaka I, Slee E, Goldin R, et al. ASPP2 is a haploinsufficient tumor suppressor that cooperates with p53 to suppress tumor growth. Genes Dev. 2006;20(10):1262\u20137. https:\/\/doi.org\/10.1101\/gad.374006. PubMed PMID: 16702401; PubMed Central PMCID: PMC1472901.","journal-title":"Genes Dev"},{"issue":"44","key":"2795_CR65","doi-asserted-by":"publisher","first-page":"17969","DOI":"10.1073\/pnas.1309362110","volume":"110","author":"L Tordella","year":"2013","unstructured":"Tordella L, Koch S, Salter V, Pagotto A, Doondeea JB, Feller SM, et al. ASPP2 suppresses squamous cell carcinoma via RelA\/p65-mediated repression of p63. Proc Natl Acad Sci U S A. 2013;110(44):17969\u201374. https:\/\/doi.org\/10.1073\/pnas.1309362110. Epub 20131014.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2795_CR66","doi-asserted-by":"publisher","unstructured":"Ferre P, Phan F, Foufelle F. SREBP-1c and lipogenesis in the liver: an update1. Biochem J. 2021;478(20):3723-39. https:\/\/doi.org\/10.1042\/BCJ20210071. PubMed PMID: 34673919.","DOI":"10.1042\/BCJ20210071"},{"key":"2795_CR67","doi-asserted-by":"publisher","first-page":"952371","DOI":"10.3389\/fonc.2022.952371","volume":"12","author":"Q Zhao","year":"2022","unstructured":"Zhao Q, Lin X, Wang G, Targeting. SREBP-1-Mediated Lipogenesis as Potential Strategies for Cancer. Front Oncol. 2022;12:952371. Epub 20220714. PubMed PMID: 35912181; PubMed Central PMCID: PMC9330218. https:\/\/doi.org\/10.3389\/fonc.2022.952371.","journal-title":"Front Oncol"},{"issue":"7524","key":"2795_CR68","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/nature13890","volume":"514","author":"RK McGinty","year":"2014","unstructured":"McGinty RK, Henrici RC, Tan S. Crystal structure of the PRC1 ubiquitylation module bound to the nucleosome. Nature. 2014;514(7524):591\u20136. https:\/\/doi.org\/10.1038\/nature13890. PubMed PMID: 25355358; PubMed Central PMCID: PMC4215650.","journal-title":"Nature"},{"key":"2795_CR69","doi-asserted-by":"publisher","unstructured":"Duan Z, Shi M, Kumaraswamy A, Lin D, Khokhani D, Wang Y et al. PROX1 is an early driver of lineage plasticity in prostate cancer. J Clin Invest. 2025;135(11). Epub 20250602. https:\/\/doi.org\/10.1172\/JCI187490. PubMed PMID: 40454483; PubMed Central PMCID: PMC12126232.","DOI":"10.1172\/JCI187490"},{"issue":"3","key":"2795_CR70","doi-asserted-by":"publisher","first-page":"81","DOI":"10.14712\/fb2023069030081","volume":"69","author":"M Jeong","year":"2023","unstructured":"Jeong M, Jung E, Oh S, Shin SY. Homeobox Protein PROX1 Expression is Negatively Regulated by Histone Deacetylase 1 and c-JUN Complex in MDA-MB-231 Human Breast Cancer Cells. Folia Biol (Praha). 2023;69(3):81\u201390. https:\/\/doi.org\/10.14712\/fb2023069030081. PubMed PMID: 38206773.","journal-title":"Folia Biol (Praha)"},{"issue":"3","key":"2795_CR71","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1242\/dev.126.3.443","volume":"126","author":"M Torii","year":"1999","unstructured":"Torii M, Matsuzaki F, Osumi N, Kaibuchi K, Nakamura S, Casarosa S, et al. Transcription factors Mash-1 and Prox-1 delineate early steps in differentiation of neural stem cells in the developing central nervous system. Development. 1999;126(3):443\u201356. https:\/\/doi.org\/10.1242\/dev.126.3.443. PubMed PMID: 9876174.","journal-title":"Development"},{"key":"2795_CR72","doi-asserted-by":"publisher","unstructured":"Wise DR, Schneider JA, Armenia J, Febles VA, McLaughlin B, Brennan R, et al. Dickkopf-1 Can Lead to Immune Evasion in Metastatic Castration-Resistant Prostate Cancer. JCO Precis Oncol. 2020;4. https:\/\/doi.org\/10.1200\/PO.20.00097. Epub 20200929.","DOI":"10.1200\/PO.20.00097"},{"key":"2795_CR73","doi-asserted-by":"publisher","unstructured":"Edirisinghe O, Ternier G, Alraawi Z, Suresh Kumar TK, Decoding FGFFGFR, Signaling. Insights into Biological Functions and Disease Relevance. Biomolecules. 2024;14(12). Epub 20241218. https:\/\/doi.org\/10.3390\/biom14121622. PubMed PMID: 39766329; PubMed Central PMCID: PMC11726770.","DOI":"10.3390\/biom14121622"},{"issue":"6","key":"2795_CR74","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.ccr.2007.11.004","volume":"12","author":"VD Acevedo","year":"2007","unstructured":"Acevedo VD, Gangula RD, Freeman KW, Li R, Zhang Y, Wang F, et al. Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition. Cancer Cell. 2007;12(6):559\u201371. PubMed PMID: 18068632.","journal-title":"Cancer Cell"},{"issue":"6","key":"2795_CR75","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1073\/pnas.0913873107","volume":"107","author":"DA Lawson","year":"2010","unstructured":"Lawson DA, Zong Y, Memarzadeh S, Xin L, Huang J, Witte ON. Basal epithelial stem cells are efficient targets for prostate cancer initiation. Proc Natl Acad Sci U S A. 2010;107(6):2610\u20135. https:\/\/doi.org\/10.1073\/pnas.0913873107. Epub 20100125.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"2795_CR76","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1111\/j.1442-2042.2005.01164.x","volume":"12","author":"H Oka","year":"2005","unstructured":"Oka H, Chatani Y, Kohno M, Kawakita M, Ogawa O. Constitutive activation of the 41- and 43-kDa mitogen-activated protein (MAP) kinases in the progression of prostate cancer to an androgen-independent state. Int J Urol. 2005;12(10):899\u2013905. x. PubMed PMID: 16323984.","journal-title":"Int J Urol"},{"issue":"5","key":"2795_CR77","doi-asserted-by":"publisher","first-page":"306","DOI":"10.62347\/JNBR1463","volume":"12","author":"S Liu","year":"2024","unstructured":"Liu S, Garcia-Marques FJ, Shen M, Bermudez A, Pitteri SJ, Stoyanova T. Ubiquitin C-terminal hydrolase L1 is a regulator of tumor growth and metastasis in double-negative prostate cancer. Am J Clin Exp Urol. 2024;12(5):306\u201322. PubMed PMID: 39584005; PubMed Central PMCID: PMC11578776.","journal-title":"Am J Clin Exp Urol"},{"issue":"11","key":"2795_CR78","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1158\/0008-5472.CAN-21-3565","volume":"82","author":"Y Rodriguez","year":"2022","unstructured":"Rodriguez Y, Unno K, Truica MI, Chalmers ZR, Yoo YA, Vatapalli R, et al. A Genome-Wide CRISPR Activation Screen Identifies PRRX2 as a Regulator of Enzalutamide Resistance in Prostate Cancer. Cancer Res. 2022;82(11):2110\u201323. https:\/\/doi.org\/10.1158\/0008-5472.CAN-21-3565. PubMed PMID: 35405009; PubMed Central PMCID: PMC9177667.","journal-title":"Cancer Res"},{"key":"2795_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.10.009","author":"CC Chen","year":"2023","unstructured":"Chen CC, Tran W, Song K, Sugimoto T, Obusan MB, Wang L, et al. Temporal evolution reveals bifurcated lineages in aggressive neuroendocrine small cell prostate cancer trans-differentiation. Cancer Cell. 2023;41(12):2066. https:\/\/doi.org\/10.1016\/j.ccell.2023.10.009. Epub 20231122. 82 e9."},{"issue":"2","key":"2795_CR80","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ccell.2019.07.006","volume":"36","author":"MM Shen","year":"2019","unstructured":"Shen MM. A Positive Step toward Understanding Double-Negative Metastatic Prostate Cancer. Cancer Cell. 2019;36(2):117\u20139. https:\/\/doi.org\/10.1016\/j.ccell.2019.07.006. PubMed PMID: 31408617.","journal-title":"Cancer Cell"},{"issue":"10","key":"2795_CR81","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/s41580-023-00615-w","volume":"24","author":"A Baysoy","year":"2023","unstructured":"Baysoy A, Bai Z, Satija R, Fan R. The technological landscape and applications of single-cell multi-omics. Nat Rev Mol Cell Biol. 2023;24(10):695\u2013713. https:\/\/doi.org\/10.1038\/s41580-023-00615-w. Epub 20230606.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2795_CR82","doi-asserted-by":"publisher","unstructured":"Schwartzman O, Tanay A. Single-cell epigenomics: techniques and emerging applications. Nat Rev Genet. 2015;16(12):716\u2009\u2013\u200926. Epub 20151013. https:\/\/doi.org\/10.1038\/nrg3980. PubMed PMID: 26460349.","DOI":"10.1038\/nrg3980"},{"issue":"3","key":"2795_CR83","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/s41592-023-01791-5","volume":"20","author":"HM Bennett","year":"2023","unstructured":"Bennett HM, Stephenson W, Rose CM, Darmanis S. Single-cell proteomics enabled by next-generation sequencing or mass spectrometry. Nat Methods. 2023;20(3):363\u201374. https:\/\/doi.org\/10.1038\/s41592-023-01791-5. Epub 20230302.","journal-title":"Nat Methods"},{"key":"2795_CR84","doi-asserted-by":"publisher","first-page":"e140923221042","DOI":"10.2174\/1874467217666230914090621","volume":"17","author":"DV Lim","year":"2024","unstructured":"Lim DV, Woo WH, Lim JX, Loh XY, Soh HT, Lim SYA, et al. Targeting Mutant-p53 for Cancer Treatment: Are We There Yet? Curr Mol Pharmacol. 2024;17:e140923221042. PubMed PMID: 37711005. https:\/\/doi.org\/10.2174\/1874467217666230914090621.","journal-title":"Curr Mol Pharmacol"},{"key":"2795_CR85","doi-asserted-by":"publisher","unstructured":"Hinterndorfer M, Spiteri VA, Ciulli A, Winter GE. Targeted protein degradation for cancer therapy. Nat Rev Cancer. 2025. Epub 20250425. https:\/\/doi.org\/10.1038\/s41568-025-00817-8. PubMed PMID: 40281114.","DOI":"10.1038\/s41568-025-00817-8"},{"issue":"1","key":"2795_CR86","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41392-022-00966-4","volume":"7","author":"L Zhao","year":"2022","unstructured":"Zhao L, Zhao J, Zhong K, Tong A, Jia D. Targeted protein degradation: mechanisms, strategies and application. Signal Transduct Target Ther. 2022;7(1):113. https:\/\/doi.org\/10.1038\/s41392-022-00966-4. Epub 20220404.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"2795_CR87","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1038\/s41467-025-57099-9","volume":"16","author":"J Liu","year":"2025","unstructured":"Liu J, Shen Y, Liu J, Xu D, Chang CY, Wang J, et al. Lipogenic enzyme FASN promotes mutant p53 accumulation and gain-of-function through palmitoylation. Nat Commun. 2025;16(1):1762. https:\/\/doi.org\/10.1038\/s41467-025-57099-9. Epub 20250219.","journal-title":"Nat Commun"},{"issue":"1","key":"2795_CR88","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s13045-020-00949-4","volume":"13","author":"J Yuan","year":"2020","unstructured":"Yuan J, Dong X, Yap J, Hu J. The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy. J Hematol Oncol. 2020;13(1):113. https:\/\/doi.org\/10.1186\/s13045-020-00949-4. Epub 20200817.","journal-title":"J Hematol Oncol"},{"issue":"2","key":"2795_CR89","doi-asserted-by":"publisher","first-page":"101381","DOI":"10.1016\/j.xcrm.2023.101381","volume":"5","author":"S Liu","year":"2024","unstructured":"Liu S, Chai T, Garcia-Marques F, Yin Q, Hsu EC, Shen M, et al. UCHL1 is a potential molecular indicator and therapeutic target for neuroendocrine carcinomas. Cell Rep Med. 2024;5(2):101381. https:\/\/doi.org\/10.1016\/j.xcrm.2023.101381. Epub 20240119.","journal-title":"Cell Rep Med"},{"issue":"1","key":"2795_CR90","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1002\/pros.24630","volume":"84","author":"MP Labrecque","year":"2024","unstructured":"Labrecque MP, Brown LG, Coleman IM, Nguyen HM, Dalrymple S, Brennen WN, et al. Targeting the fibroblast growth factor pathway in molecular subtypes of castration-resistant prostate cancer. Prostate. 2024;84(1):100\u201310. https:\/\/doi.org\/10.1002\/pros.24630. Epub 20231005.","journal-title":"Prostate"},{"issue":"1","key":"2795_CR91","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12943-020-01165-x","volume":"19","author":"H Yang","year":"2020","unstructured":"Yang H, Zhang Q, Xu M, Wang L, Chen X, Feng Y, et al. CCL2-CCR2 axis recruits tumor associated macrophages to induce immune evasion through PD-1 signaling in esophageal carcinogenesis. Mol Cancer. 2020;19(1):41. https:\/\/doi.org\/10.1186\/s12943-020-01165-x. Epub 20200227.","journal-title":"Mol Cancer"},{"issue":"4","key":"2795_CR92","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/cmi.2017.135","volume":"15","author":"T Yoshimura","year":"2018","unstructured":"Yoshimura T. The chemokine MCP-1 (CCL2) in the host interaction with cancer: a foe or ally? Cell Mol Immunol. 2018;15(4):335\u201345. https:\/\/doi.org\/10.1038\/cmi.2017.135. Epub 20180129.","journal-title":"Cell Mol Immunol"},{"issue":"6","key":"2795_CR93","doi-asserted-by":"publisher","first-page":"e1646","DOI":"10.1002\/wsbm.1646","volume":"16","author":"BN Rodriguez","year":"2024","unstructured":"Rodriguez BN, Huang H, Chia JJ, Hoffmann A. The noncanonical NFkappaB pathway: Regulatory mechanisms in health and disease. WIREs Mech Dis. 2024;16(6):e1646. https:\/\/doi.org\/10.1002\/wsbm.1646. Epub 20240418.","journal-title":"WIREs Mech Dis"},{"issue":"8","key":"2795_CR94","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1158\/0008-5472.CAN-19-2948","volume":"80","author":"HR Cha","year":"2020","unstructured":"Cha HR, Lee JH, Ponnazhagan S. Revisiting Immunotherapy: A Focus on Prostate Cancer. Cancer Res. 2020;80(8):1615\u201323. Epub 20200217. PubMed PMID: 32066566; PubMed Central PMCID: PMC7641094. https:\/\/doi.org\/10.1158\/0008-5472.CAN-19-2948.","journal-title":"Cancer Res"},{"issue":"18","key":"2795_CR95","doi-asserted-by":"publisher","first-page":"6913","DOI":"10.7150\/thno.100555","volume":"14","author":"SB Hansen","year":"2024","unstructured":"Hansen SB, Unal B, Kuzu OF, Saatcioglu F. Immunological facets of prostate cancer and the potential of immune checkpoint inhibition in disease management. Theranostics. 2024;14(18):6913\u201334. https:\/\/doi.org\/10.7150\/thno.100555. Epub 20241021.","journal-title":"Theranostics"},{"issue":"19","key":"2795_CR96","doi-asserted-by":"publisher","first-page":"9417","DOI":"10.1158\/0008-5472.CAN-07-1286","volume":"67","author":"RD Loberg","year":"2007","unstructured":"Loberg RD, Ying C, Craig M, Day LL, Sargent E, Neeley C, et al. Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo. Cancer Res. 2007;67(19):9417\u201324. https:\/\/doi.org\/10.1158\/0008-5472.CAN-07-1286. PubMed PMID: 17909051.","journal-title":"Cancer Res"},{"issue":"7","key":"2795_CR97","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1593\/neo.07307","volume":"9","author":"RD Loberg","year":"2007","unstructured":"Loberg RD, Ying C, Craig M, Yan L, Snyder LA, Pienta KJ. CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration. Neoplasia. 2007;9(7):556\u201362. https:\/\/doi.org\/10.1593\/neo.07307. PubMed PMID: 17710158; PubMed Central PMCID: PMC1939930.","journal-title":"Neoplasia"},{"key":"2795_CR98","doi-asserted-by":"publisher","first-page":"115318","DOI":"10.1016\/j.addr.2024.115318","volume":"209","author":"S Pozzi","year":"2024","unstructured":"Pozzi S, Satchi-Fainaro R. The role of CCL2\/CCR2 axis in cancer and inflammation: The next frontier in nanomedicine. Adv Drug Deliv Rev. 2024;209:115318. https:\/\/doi.org\/10.1016\/j.addr.2024.115318. Epub 20240421.","journal-title":"Adv Drug Deliv Rev"},{"issue":"8","key":"2795_CR99","doi-asserted-by":"publisher","first-page":"100918","DOI":"10.1016\/j.xinn.2025.100918","volume":"6","author":"P Song","year":"2025","unstructured":"Song P, Jiang Q, Wu X, Bu L, Xie W, Wei W, et al. Palmitic acid and palmitoylation in cancer: Understanding, insights, and challenges. Innov (Camb). 2025;6(8):100918. https:\/\/doi.org\/10.1016\/j.xinn.2025.100918. Epub 20250429.","journal-title":"Innov (Camb)"},{"issue":"3","key":"2795_CR100","doi-asserted-by":"publisher","first-page":"e15186","DOI":"10.1002\/advs.202515186","volume":"13","author":"JE Yun","year":"2026","unstructured":"Yun JE, Seo J, Koh J, Im SA, Hong KY, Son Y, et al. Cancer Manipulates Adjacent Adipose Tissue to Exploit Fatty Acids via HIF-1alpha\/CCL2\/PPARalpha Axis: A Metabolic Circuit to Support Tumor Progression. Adv Sci (Weinh). 2026;13(3):e15186. https:\/\/doi.org\/10.1002\/advs.202515186. Epub 20251029.","journal-title":"Adv Sci (Weinh)"},{"key":"2795_CR101","doi-asserted-by":"publisher","first-page":"771210","DOI":"10.3389\/fimmu.2021.771210","volume":"12","author":"L Fei","year":"2021","unstructured":"Fei L, Ren X, Yu H, Zhan Y. Targeting the CCL2\/CCR2 Axis in Cancer Immunotherapy: One Stone. Three Birds? Front Immunol. 2021;12:771210. Epub 20211103. PubMed PMID: 34804061; PubMed Central PMCID: PMC8596464. https:\/\/doi.org\/10.3389\/fimmu.2021.771210.","journal-title":"Three Birds? Front Immunol"},{"issue":"4","key":"2795_CR102","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1016\/j.apsb.2022.10.027","volume":"13","author":"M Zheng","year":"2023","unstructured":"Zheng M, Zhang W, Chen X, Guo H, Wu H, Xu Y, et al. The impact of lipids on the cancer-immunity cycle and strategies for modulating lipid metabolism to improve cancer immunotherapy. Acta Pharm Sin B. 2023;13(4):1488\u201397. https:\/\/doi.org\/10.1016\/j.apsb.2022.10.027. Epub 20221102.","journal-title":"Acta Pharm Sin B"},{"key":"2795_CR103","doi-asserted-by":"publisher","unstructured":"Wang MS, Sussman J, Xu JA, Patel R, Elghawy O, Rawla P. Pharmacological Advancements of PRC2 in Cancer Therapy: A Narrative Review. Life (Basel). 2024;14(12). Epub 20241211. https:\/\/doi.org\/10.3390\/life14121645. PubMed PMID: 39768352; PubMed Central PMCID: PMC11678550.","DOI":"10.3390\/life14121645"},{"issue":"5","key":"2795_CR104","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1158\/2326-6066.CIR-22-0317","volume":"11","author":"L Li","year":"2023","unstructured":"Li L, Hao S, Gao M, Liu J, Xu X, Huang J, et al. HDAC3 Inhibition Promotes Antitumor Immunity by Enhancing CXCL10-Mediated Chemotaxis and Recruiting of Immune Cells. Cancer Immunol Res. 2023;11(5):657\u201373. https:\/\/doi.org\/10.1158\/2326-6066.CIR-22-0317. PubMed PMID: 36898011; PubMed Central PMCID: PMC10155037.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"2795_CR105","doi-asserted-by":"publisher","first-page":"6731","DOI":"10.1038\/s41467-023-42417-w","volume":"14","author":"A Goyal","year":"2023","unstructured":"Goyal A, Bauer J, Hey J, Papageorgiou DN, Stepanova E, Daskalakis M, et al. DNMT and HDAC inhibition induces immunogenic neoantigens from human endogenous retroviral element-derived transcripts. Nat Commun. 2023;14(1):6731. https:\/\/doi.org\/10.1038\/s41467-023-42417-w. Epub 20231023.","journal-title":"Nat Commun"},{"issue":"2","key":"2795_CR106","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. N Engl J Med. 2018;378(2):158\u201368. PubMed PMID: 29320654. https:\/\/doi.org\/10.1056\/NEJMra1703481.","journal-title":"N Engl J Med"},{"issue":"3","key":"2795_CR107","doi-asserted-by":"publisher","first-page":"466","DOI":"10.21147\/j.issn.1000-9604.2025.03.13","volume":"37","author":"M Li","year":"2025","unstructured":"Li M, Zhou R, Qiu Y, Peng Y, Liu M, Zhang X. Molecular insights into immune evasion and therapeutic paradigms in pancreatic cancer. Chin J Cancer Res. 2025;37(3):466\u201386. https:\/\/doi.org\/10.21147\/j.issn.1000-9604.2025.03.13. PubMed PMID: 40642496; PubMed Central PMCID: PMC12240239.","journal-title":"Chin J Cancer Res"},{"key":"2795_CR108","doi-asserted-by":"publisher","unstructured":"Qin L, Liang T, Zhu X, Hu W, Li B, Wei M et al. Senescent Macrophages and the Lung Cancer Microenvironment: A New Perspective on Tumor Immune Evasion. Aging Dis. 2024. Epub 20241231. PubMed PMID: 39751858. https:\/\/doi.org\/10.14336\/AD.2024.1404.","DOI":"10.14336\/AD.2024.1404"},{"key":"2795_CR109","doi-asserted-by":"publisher","unstructured":"Turnham DJ, Mullen MS, Bullock NP, Gilroy KL, Richards AE, Patel R et al. Development and Characterisation of a New Patient-Derived Xenograft Model of AR-Negative Metastatic Castration-Resistant Prostate Cancer. Cells. 2024;13(8). Epub 20240412. https:\/\/doi.org\/10.3390\/cells13080673. PubMed PMID: 38667288; PubMed Central PMCID: PMC11049137.","DOI":"10.3390\/cells13080673"},{"issue":"1","key":"2795_CR110","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13000-024-01511-3","volume":"19","author":"D Akhoundova","year":"2024","unstructured":"Akhoundova D, Fischer S, Triscott J, Lehner M, Thienger P, Maletti S, et al. Rare histologic transformation of a CTNNB1 (beta-catenin) mutated prostate cancer with aggressive clinical course. Diagn Pathol. 2024;19(1):83. https:\/\/doi.org\/10.1186\/s13000-024-01511-3. Epub 20240621.","journal-title":"Diagn Pathol"},{"issue":"3","key":"2795_CR111","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1053\/j.semdp.2024.05","volume":"41","author":"DY Mebratie","year":"2024","unstructured":"Mebratie DY, Dagnaw GG. Review of immunohistochemistry techniques: Applications, current status, and future perspectives. Semin Diagn Pathol. 2024;41(3):154\u201360. https:\/\/doi.org\/10.1053\/j.semdp.2024.05. Epub 20240503.","journal-title":"Semin Diagn Pathol"},{"issue":"3","key":"2795_CR112","doi-asserted-by":"publisher","first-page":"e70001","DOI":"10.1002\/wsbm.70001","volume":"17","author":"N Rajinikanth","year":"2025","unstructured":"Rajinikanth N, Chauhan R, Prabakaran S. Harnessing Noncanonical Proteins for Next-Generation Drug Discovery and Diagnosis. WIREs Mech Dis. 2025;17(3):e70001. https:\/\/doi.org\/10.1002\/wsbm.70001. PubMed PMID: 40423871; PubMed Central PMCID: PMC12109379.","journal-title":"WIREs Mech Dis"},{"key":"2795_CR113","doi-asserted-by":"publisher","first-page":"102699","DOI":"10.1016\/j.ctrv.2024.102699","volume":"125","author":"EF Giunta","year":"2024","unstructured":"Giunta EF, Brighi N, Gurioli G, Matteucci F, Paganelli G, De Giorgi U. 177Lu-PSMA therapy in metastatic prostate cancer: An updated review of prognostic and predictive biomarkers. Cancer Treat Rev. 2024;125:102699. https:\/\/doi.org\/10.1016\/j.ctrv.2024.102699. Epub 20240217.","journal-title":"Cancer Treat Rev"},{"key":"2795_CR114","doi-asserted-by":"publisher","first-page":"1612181","DOI":"10.3389\/pore.2025.1612181","volume":"31","author":"TR Linkner","year":"2025","unstructured":"Linkner TR, Nagy ZB, Kalmar A, Farkas E, Banyai F, Szakallas N, et al. Circulating tumor cells: indicators of cancer progression, plasticity and utility for therapies. Pathol Oncol Res. 2025;31:1612181. https:\/\/doi.org\/10.3389\/pore.2025.1612181. Epub 20251020.","journal-title":"Pathol Oncol Res"},{"key":"2795_CR115","doi-asserted-by":"publisher","unstructured":"Liu T, Li Z, Chen S, Zhong J. Circulating Cell-free DNA Fragmentomics Detection and Beyond. Aging Dis. 2025. Epub 20250904. PubMed PMID: 40956966. https:\/\/doi.org\/10.14336\/AD.2025.1029.","DOI":"10.14336\/AD.2025.1029"},{"issue":"1","key":"2795_CR116","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12943-019-0989-z","volume":"18","author":"L Zhang","year":"2019","unstructured":"Zhang L, Liang Y, Li S, Zeng F, Meng Y, Chen Z, et al. The interplay of circulating tumor DNA and chromatin modification, therapeutic resistance, and metastasis. Mol Cancer. 2019;18(1):36. https:\/\/doi.org\/10.1186\/s12943-019-0989-z. Epub 20190309.","journal-title":"Mol Cancer"},{"issue":"3","key":"2795_CR117","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1200\/JCO.2016.69.9751","volume":"35","author":"KM Cunanan","year":"2017","unstructured":"Cunanan KM, Gonen M, Shen R, Hyman DM, Riely GJ, Begg CB, et al. Basket Trials in Oncology: A Trade-Off Between Complexity and Efficiency. J Clin Oncol. 2017;35(3):271\u20133. https:\/\/doi.org\/10.1200\/JCO.2016.69.9751. Epub 20161128.","journal-title":"J Clin Oncol"},{"issue":"2","key":"2795_CR118","first-page":"125","volume":"70","author":"JJH Park","year":"2020","unstructured":"Park JJH, Hsu G, Siden EG, Thorlund K, Mills EJ. An overview of precision oncology basket and umbrella trials for clinicians. CA Cancer J Clin. 2020;70(2):125\u201337. PubMed PMID: 32031692; PubMed Central PMCID: PMC7187272.","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"2795_CR119","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1002\/iju5.12766","volume":"7","author":"H Tanaka","year":"2024","unstructured":"Tanaka H, Yoshida S, Aoyama S, Ikeda S, Kunieda J, Ohashi K, et al. A case of double-negative prostate cancer with BRCA2 mutation and high tumor mutation burden treated sequentially with olaparib and pembrolizumab. IJU Case Rep. 2024;7(5):395\u20138. https:\/\/doi.org\/10.1002\/iju5.12766. Epub 20240804.","journal-title":"IJU Case Rep"},{"issue":"4","key":"2795_CR120","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3978\/j.issn.2304-3865.2014.06","volume":"3","author":"Y Zang","year":"2014","unstructured":"Zang Y, Lee JJ. Adaptive clinical trial designs in oncology. Chin Clin Oncol. 2014;3(4):49. https:\/\/doi.org\/10.3978\/j.issn.2304-3865.2014.06. .04. PubMed PMID: 25841530.","journal-title":"Chin Clin Oncol"},{"key":"2795_CR121","doi-asserted-by":"publisher","unstructured":"Pathak R, Villaflor VM. Histologic Transformation in EGFR-Mutant Lung Adenocarcinomas: Mechanisms and Therapeutic Implications. Cancers (Basel). 2021;13(18). Epub 20210916. PubMed PMID: 34572868; PubMed Central PMCID: PMC8470834. https:\/\/doi.org\/10.3390\/cancers13184641.","DOI":"10.3390\/cancers13184641"},{"issue":"4","key":"2795_CR122","first-page":"100831","volume":"6","author":"S Li","year":"2025","unstructured":"Li S, Zhao W, An Q, Wang L, Zhu M, Ni J, et al. Novel cancer stem cell-targeted retinoid ZSH-512 impedes colorectal cancer progress via KDM3A-mediated epigenetic reprogramming. Innov (Camb). 2025;6(4):100831. PubMed PMID: 40470327; PubMed Central PMCID: PMC12130993.","journal-title":"Innov (Camb)"},{"issue":"12","key":"2795_CR123","doi-asserted-by":"publisher","first-page":"eads9182","DOI":"10.1126\/sciadv.ads9182","volume":"11","author":"MB Eduardo","year":"2025","unstructured":"Eduardo MB, Cottone G, McCloskey CW, Liu S, Palma FR, Zappia MP, et al. A metabolic shift to the serine pathway induced by lipids fosters epigenetic reprogramming in nontransformed breast cells. Sci Adv. 2025;11(12):eads9182. https:\/\/doi.org\/10.1126\/sciadv.ads9182. Epub 20250321.","journal-title":"Sci Adv"},{"issue":"11","key":"2795_CR124","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/s41571-020-0411-1","volume":"17","author":"RA Gatenby","year":"2020","unstructured":"Gatenby RA, Brown JS. Integrating evolutionary dynamics into cancer therapy. Nat Rev Clin Oncol. 2020;17(11):675\u201386. https:\/\/doi.org\/10.1038\/s41571-020-0411-1. Epub 20200722.","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"2795_CR125","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/s41588-020-0668-4","volume":"52","author":"N Zahir","year":"2020","unstructured":"Zahir N, Sun R, Gallahan D, Gatenby RA, Curtis C. Characterizing the ecological and evolutionary dynamics of cancer. Nat Genet. 2020;52(8):759\u201367. https:\/\/doi.org\/10.1038\/s41588-020-0668-4. Epub 20200727.","journal-title":"Nat Genet"},{"issue":"7868","key":"2795_CR126","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41586-021-03648-3","volume":"595","author":"S Salehi","year":"2021","unstructured":"Salehi S, Kabeer F, Ceglia N, Andronescu M, Williams MJ, Campbell KR, et al. Clonal fitness inferred from time-series modelling of single-cell cancer genomes. Nature. 2021;595(7868):585\u201390. https:\/\/doi.org\/10.1038\/s41586-021-03648-3. Epub 20210623.","journal-title":"Nature"},{"issue":"1","key":"2795_CR127","doi-asserted-by":"publisher","first-page":"4209","DOI":"10.1038\/s41467-025-59397-8","volume":"16","author":"A Khalil","year":"2025","unstructured":"Khalil A, Supek F. DiffInvex identifies evolutionary shifts in driver gene repertoires during tumorigenesis and chemotherapy. Nat Commun. 2025;16(1):4209. Epub 20250513. PubMed PMID: 40360478; PubMed Central PMCID: PMC12075687. https:\/\/doi.org\/10.1038\/s41467-025-59397-8.","journal-title":"Nat Commun"}],"container-title":["Cell Communication and Signaling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12964-026-02795-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-026-02795-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-026-02795-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T23:54:38Z","timestamp":1777852478000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12964-026-02795-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":127,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2795"],"URL":"https:\/\/doi.org\/10.1186\/s12964-026-02795-2","relation":{"references":[{"id-type":"doi","id":"10.1016\/j.ccell.2019.06.009","asserted-by":"subject"},{"id-type":"doi","id":"10.1016\/j.ccell.2023.10.009","asserted-by":"subject"}]},"ISSN":["1478-811X"],"issn-type":[{"value":"1478-811X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,25]]},"assertion":[{"value":"21 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"264"}}